A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Subjects.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Rilpivirine (Primary) ; Efavirenz
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Tibotec Inc
- 06 Jan 2011 New trial record